Monopar Pharma (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Monopar Pharma (MNPR)

The Monopar Therapeutics (MNPR) clinical portfolio is characterized by a high dependency on a single radiopharmaceutical project, which creates binary risks for share price growth. This chart illustrates an EV/EBITDA ratio of 0.00, complementing data on the biotech's partnerships with leading medical centers. The business relies on the development of isotopic tumor treatments, utilizing an asset-light approach and monoclonal antibodies to scale trials.

MNPR Monopar Therapeutics Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/12/2026

MNPR (monopartx.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Monopar Pharma|MNPR - Fair Value Consensus
- market capitalization indicators:
Market Value Monopar Corp|MNPR - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Monopar Therapeutics|MNPR - Accounting Capitalization|Market Capitalization to Book Value Ratio monopartx.com|MNPR - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Monopar Therapeutics|MNPR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Monopar Therapeutics Inc.|MNPR - Company Debts|Debt to Book Capitalization Ratio Monopar Corp|MNPR - Long-Term Debt|Company Short-Term Debts Monopar Therapeutics|Quick Liquidity Indicator monopartx.com
- business earnings and investment ratios data:
MNPR - Company Net Income|Future Profit Monopar Therapeutics|MNPR - Company Value to Net Income|Projected Price to Earnings Monopar Therapeutics|MNPR - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Monopar Corp|MNPR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Monopar Therapeutics|MNPR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months monopartx.com|MNPR - Earnings per share increase in current year|Earnings growth forecast for next year Monopar Therapeutics
Summary company analytics:MNPR (Monopar Pharma)
Original product of Monopar Therapeutics Inc.

As a portfolio manager, I utilize this instrument to determine the fair value of the business. The current EV/EBITDA multiple compares the total enterprise value to its operating profit, excluding the impact of the tax regime and debt load. This trend captures the capitalization efficiency of Monopar Therapeutics (MNPR) technological assets. The robotization of bio-screening and the implementation of AI optimize costs, which directly impacts the company's fundamental valuation.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Inhibrx Biosciences, Inc. (INBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation IMAB|FENC (Fennec Pharmaceuticals Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Heron Therapeutics Inc (HRTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc. (NVCT)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)